3.5 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | intake_tier | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | What's the True Risk for Eating Disorders With GLP-1s? | STAT News | https://www.statnews.com/2026/04/27/health-news-true-risk-of-eating-disorders-and-wegovy-ozempic/ | 2026-04-27 | health | article | unprocessed | high |
|
research-task |
Content
STAT News investigative feature (April 27, 2026) on the evidence base for eating disorder risk with GLP-1 medications.
Key finding — ISPOR real-world analysis:
- More than 60,000 people taking GLP-1s analyzed via medical records
- 1.28% diagnosed with eating disorder within two years
- Note: This is total incidence in GLP-1 users — no control group for comparison (limitation)
Scale calculation: If ~1 in 8 Americans takes a GLP-1, more than 420,000 people could develop an eating disorder based on this rate.
Expert assessment: "Physicians, trialists, regulators, policymakers, and drug developers are unprepared for this coming wave" — attributed to "Banks" (identity unclear in search results).
Research gap acknowledged: "Actual research on this topic is scant" — the article explicitly characterizes the evidence base as insufficient.
Full article content inaccessible (subscription/paywall — STAT News). Full summary above derived from search result excerpts and corroborating sources.
Agent Notes
Why this matters: STAT News has the most credibility among health science journalists for quantitative accuracy. The April 27, 2026 date (one week ago) makes this the most current synthesis available. The 1.28% figure is the best available real-world incidence estimate, even without controls.
What surprised me: The STAT News framing "true risk" in the headline suggests the article is specifically addressing the causality vs. population-selection debate — this is exactly the question from this session. Unfortunately the full article is paywalled.
What I expected but didn't find: Full article content — it's behind the STAT News paywall. The extract doesn't give the full causality assessment.
KB connections: healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care — analogous structure: increasing GLP-1 access induces more eating disorder exposure.
Extraction hints: The 1.28% incidence figure needs careful scoping: this is total incidence in GLP-1 users, not GLP-1 vs. matched controls. The 420,000 person projection is a useful frame for the scale of risk even if the causal fraction is uncertain.
Context: STAT News — most credible independent health science journalism publication in the US. This is the article that will likely drive regulatory and clinical attention to the eating disorder signal.
Curator Notes
PRIMARY CONNECTION: GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035
WHY ARCHIVED: This is the most current synthesis of the eating disorder risk question from the most credible health journalism source. The 1.28% figure and the "420,000 people" projection give the extractor a population-scale frame for the claim.
EXTRACTION HINT: Use the 1.28% figure CAREFULLY — scope to "incidence in GLP-1 user population without controlled comparison" rather than "GLP-1 causes 1.28% ED rate." The missing control group is the critical methodological gap.